2019 Hong Kong IPO Analytics: Highlight of Brokers’ and Sectors’ Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
788 Views
Hansoh Pharma's Lock-Up Expiry: Valuation and the Trade
Lock-up restriction for Hansoh Pharma's controlling shareholder, pre-IPO investors and cornerstone investors will expire on December 14th. We...
583 Views
Hansoh Pharma's Lock-Up Expiry - New Drugs Offset the Impact of Centralized Procurement
Lock-up restriction for Hansoh Pharma's controlling shareholder, pre-IPO investors and cornerstone investors will expire on December 14th. As we...
561 Views
Hansoh Pharma's HS-10296 - How Far Is It From Billion $ Tagrisso? Our Read on Phase 2 Reports
Hansoh Pharma, a leading China-based pharmaceutical company, recorded a stellar post-IPO performance since its listing in June. As a big portion of...
554 Views
ECM Weekly (6 Oct 2019) - Latitude Financial, Bytedance, Youdao, 36Kr, Ujjivan SFB
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
920 Views